ImmunoGen, Inc. (NASDAQ:IMGN) Q4 2022 Earnings Conference Call March 1, 2023 8:00 AM ET

Company Participants

Anabel Chan - Head, IR

Mark Enyedy - President and CEO

Anna Berkenblit - Chief Medical Officer

Renee Lentini - Interim-CFO

Todd Talarico - Interim-Chief Commercial Officer

Conference Call Participants

John Newman - Canaccord Genuity

Michael Schmidt - Guggenheim

Etzer Darout - BMO Capital Markets

Boris Peaker - Cowen

Andy Hsieh - William Blair

Kelly Shi - Jefferies

Asthika Goonewardene - Truist

Daniel Wolle - JPMorgan

Jonathan Chang - SVB Securities

Peter Lawson - Barclays

Operator

Good morning, and welcome to ImmunoGen's Fourth Quarter and Full Year 2022 Financial and Operating Results Conference Call. Today's conference is being recorded.

At this time, I'd like to turn the call over to Anabel Chan, Head of Investor Relations. Please go ahead.

Anabel Chan

Good morning, and thank you for joining today's call. Earlier today, we issued a press release that includes a summary of our recent operating progress and fourth quarter and full year 2022 financial results. This press release, a recording of this call and an updated corporate deck can be found under the Investors and Media section of our website at immunogen.com.

With me today are Mark Enyedy, our President and CEO; Anna Berkenblit, our Chief Medical Officer; and Renee Lentini, our Interim-CFO. Michael Vasconcelles, our EVP of Research, Development and Medical Affairs; and Todd Talarico, our Interim-Chief Commercial Officer will join us for Q&A.

During today's call, we will review recent accomplishments for the business, our financial results and highlight upcoming anticipated events. We will be making forward-looking statements based on our current expectations and beliefs. These statements are subject to risks and uncertainties, and our actual results may differ materially. Please consult the risks outlined in our press release issued this morning in the Risk Factors section of our most recent annual report on Form 10-K and in our other SEC filings, which are available at sec.gov and immunogen.com.

With that, I'll turn the call over to Mark.

Mark Enyedy

Thanks, Anabel. Good morning and thank you for joining us today.

2022 was a landmark year for ImmunoGen with significant progress on multiple fronts highlighted by the approval and launch of ELAHERE as the first and only ADC for the treatment of platinum-resistant ovarian cancer encouraging data from our second pivotal program, PVAC advances in our early stage programs, including reaching the recommended Phase 2 dose for 936 and initiating Phase 1 development with 151, rebuilding our rebuilding our pipeline through collaborations with Oxford BioTherapeutics and [Biocean], and strengthening our management team with Michael Vasconcelles in a newly created role as Executive Vice President, Research, Development and Medical Affairs; and Daniel Char, as General Counsel.